244 related articles for article (PubMed ID: 18655905)
1. Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260.
Molnár AH; Varga C; Berkó A; Rojik I; Párducz A; László F; László FA
Prog Brain Res; 2008; 170():519-25. PubMed ID: 18655905
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
Molnár AH; Varga C; Berkó A; Rojik I; Párducz A; László F; László FA
Acta Neurochir (Wien); 2008 Mar; 150(3):265-71. PubMed ID: 18288441
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.
László FA; Varga C; Nakamura S
Eur J Pharmacol; 1999 Jan; 364(2-3):115-22. PubMed ID: 9932713
[TBL] [Abstract][Full Text] [Related]
4. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
5. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
[TBL] [Abstract][Full Text] [Related]
6. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
[TBL] [Abstract][Full Text] [Related]
7. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260.
Molnár AH; Varga C; Janáky T; Tóth G; Tóth G; Farkas J; László F; László FA
Regul Pept; 2007 Jun; 141(1-3):12-8. PubMed ID: 17258819
[TBL] [Abstract][Full Text] [Related]
8. [The effect of arginine vasopressin receptor antagonist on the rat cold-injured brain].
Kagawa M; Nagao S
No Shinkei Geka; 1993 Dec; 21(12):1103-7. PubMed ID: 8259220
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
Takeuchi M; Lee JD; Shimizu H; Ueda T
Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
[TBL] [Abstract][Full Text] [Related]
10. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats.
Kazama I; Arata T; Michimata M; Hatano R; Suzuki M; Miyama N; Sanada S; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Nephrol Dial Transplant; 2007 Jan; 22(1):68-76. PubMed ID: 16702208
[TBL] [Abstract][Full Text] [Related]
11. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin antagonist improves renal function in a rat model of pneumoperitoneum.
Dolgor B; Kitano S; Yoshida T; Bandoh T; Ninomiya K; Matsumoto T
J Surg Res; 1998 Oct; 79(2):109-14. PubMed ID: 9758724
[TBL] [Abstract][Full Text] [Related]
14. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia.
Vakili A; Kataoka H; Plesnila N
J Cereb Blood Flow Metab; 2005 Aug; 25(8):1012-9. PubMed ID: 15744246
[TBL] [Abstract][Full Text] [Related]
15. In vivo diuretic effect of a new non-peptide arginine vasopressin antagonist, OPC-31260, in conscious rats.
Tsuboi Y; Ishikawa S; Fujisawa G; Okada K; Saito T
J Endocrinol; 1994 Nov; 143(2):227-34. PubMed ID: 7829988
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
[TBL] [Abstract][Full Text] [Related]
17. Targeted overexpression of endothelin-1 in astrocytes leads to more severe cytotoxic brain edema and higher mortality.
Yeung PK; Lo AC; Leung JW; Chung SS; Chung SK
J Cereb Blood Flow Metab; 2009 Dec; 29(12):1891-902. PubMed ID: 19707218
[TBL] [Abstract][Full Text] [Related]
18. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
Hirano T; Yamamura Y; Nakamura S; Onogawa T; Mori T
J Pharmacol Exp Ther; 2000 Jan; 292(1):288-94. PubMed ID: 10604960
[TBL] [Abstract][Full Text] [Related]
19. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
20. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs.
Grove L; Christensen P; Bie P
Acta Physiol Scand; 1998 May; 163(1):93-101. PubMed ID: 9648627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
